CliffBio
small molecule

ADVIL DUAL ACTION WITH ACETAMINOPHEN

ACETAMINOPHEN; IBUPROFEN

Loss of exclusivityJuly 2041latest FDA-listed patent expiry
CompanyHaleon →See this company's full patent-cliff portfolio

Drug detail

Brand nameADVIL DUAL ACTION WITH ACETAMINOPHEN
Active ingredientACETAMINOPHEN; IBUPROFEN
Strength250MG;125MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2020
Marketing statusOTC

Listed patents

PatentExpiresType
11918693July 2041product

More from Haleon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADVIL DUAL ACTION WITH ACETAMINOPHEN patent cliff — loss of exclusivity July 2041 | CliffBio